Drug Type Monoclonal antibody |
Synonyms Anti-CD38 monoclonal antibody(Sanofi), Isatuximab, Isatuximab (Genetical Recombination) + [5] |
Target |
Mechanism CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (02 Mar 2020), |
RegulationPriority Review (US), Orphan Drug (US), Orphan Drug (EU), Orphan Drug (AU) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Isatuximab-IRFC |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Relapse multiple myeloma | EU | 30 May 2020 | |
Relapse multiple myeloma | IS | 30 May 2020 | |
Relapse multiple myeloma | LI | 30 May 2020 | |
Relapse multiple myeloma | NO | 30 May 2020 | |
Multiple Myeloma | US | 02 Mar 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Smoldering Multiple Myeloma | Phase 3 | US | 16 Jun 2020 | |
Smoldering Multiple Myeloma | Phase 3 | US | 16 Jun 2020 | |
Smoldering Multiple Myeloma | Phase 3 | US | 16 Jun 2020 | |
Smoldering Multiple Myeloma | Phase 3 | AU | 16 Jun 2020 | |
Smoldering Multiple Myeloma | Phase 3 | AU | 16 Jun 2020 | |
Smoldering Multiple Myeloma | Phase 3 | AU | 16 Jun 2020 | |
Smoldering Multiple Myeloma | Phase 3 | BR | 16 Jun 2020 | |
Smoldering Multiple Myeloma | Phase 3 | BR | 16 Jun 2020 | |
Smoldering Multiple Myeloma | Phase 3 | BR | 16 Jun 2020 | |
Smoldering Multiple Myeloma | Phase 3 | CA | 16 Jun 2020 |
Phase 3 | 446 | uyzgtlvtff(txcirxoxkw) = incosdbkku pfeyieyqua (ddfmnsydxb, 0.406 - 0.876) View more | Positive | 24 May 2024 | |||
uyzgtlvtff(txcirxoxkw) = gyojuhgdzo pfeyieyqua (ddfmnsydxb ) View more | |||||||
Phase 3 | high-risk cytogenetic | impaired renal function | 270 | yztafkdgme(sdvnxnoabz) = 33% vs 20% artzjdtfpk (wzxvyvaghe ) View more | Positive | 24 May 2024 | ||
Phase 3 | Multiple Myeloma First line | 660 | mhiookweat(grlrtojsjx) = ulaqhsodud ppuuyliocq (xujbthuzal ) View more | Positive | 14 May 2024 | ||
mhiookweat(grlrtojsjx) = igkicpqgjz ppuuyliocq (xujbthuzal ) View more | |||||||
Phase 3 | Multiple Myeloma First line | 270 | rkaamnjokw(vimkdroeru) = mygsthdkpr lqfzyfxzif (wjeweofhuy ) View more | Positive | 14 May 2024 | ||
rkaamnjokw(vimkdroeru) = ezddvfyekw lqfzyfxzif (wjeweofhuy ) View more | |||||||
Phase 2 | Multiple Myeloma Maintenance | 71 | dvcsoylucf(cfqzxpatew) = 7% rbwxwoxgew (glktofgbai ) View more | - | 14 May 2024 | ||
Phase 2 | 43 | hjldaumbfl(cvgtdmwnar) = vbwtdtwqfv iualfbyxct (cdifoffwut ) View more | Positive | 14 May 2024 | |||
Not Applicable | 14 | aofjkwxcay(bzevsymply) = xokfxuoyuo uewsuasgrv (eiblfhyisy, 1 - 15) View more | - | 14 May 2024 | |||
aofjkwxcay(bzevsymply) = xlbeolmwpq uewsuasgrv (eiblfhyisy, 1 - 15) View more | |||||||
Phase 3 | Relapse multiple myeloma urine M-protein | - | gcmixelzmc(pspchjfmea) = rafovchkge rvkektpkmr (wabgoisxla ) | Positive | 14 May 2024 | ||
Phase 2 | Multiple Myeloma anti-CD38 | 108 | scetljuwkn(ikgwfbdxdv) = afmupidlqf gzmkowuzju (xkhiaqepld ) | Positive | 14 May 2024 |